Prospective evaluation of standard chemotherapy regimen of idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukemia (AML).
Phase of Trial: Phase II
Latest Information Update: 25 Aug 2018
At a glance
- Drugs Cytarabine (Primary) ; Idarubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 17 Jan 2017 Status changed from active, no longer recruiting to completed.
- 09 Nov 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 10 Nov 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2017 as reported by ClinicalTrials.gov